Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV₁ level: a patient-level pooled analysis of phase-3 randomized clinical trials.

ABSTRACT:

Background

Which patients should receive dual therapy as initial treatment for chronic obstructive pulmonary disease (COPD) is only loosely defined. We evaluated if a lower forced expiratory volume in 1 s (FEV₁) identifies a population more likely to benefit from dual therapy than monotherapy among group B COPD patients in whom Global initiative for Chronic Obstructive Pulmonary Disease (GOLD) recommends monotherapy as initial treatment.

Methods

This was a patient-level pooled analysis of phase-3 randomized controlled trials involving dual bronchodilators. Study patients were classified into two groups based on the FEV₁ of 50% of the predicted value (GOLD I/II versus GOLD III/IV). We evaluated the efficacy of dual versus monotherapy (long-acting beta-2

SUBMITTER: Kang J 

PROVIDER: S-EPMC7881547 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature